- Ofichem Group has acquired Avivia B.V., a formulation development specialist based in the Netherlands.
- The acquisition strengthens Ofichem’s capabilities as an integrated CDMO, offering expanded services from early development to GMP manufacturing.
Ofichem Group has signed a definitive agreement to acquire Avivia B.V., a contract development organisation based in Nijmegen, the Netherlands. Avivia specialises in formulation development, analytical method development, and excipient characterisation.
The acquisition supports Ofichem’s strategic aim to become a fully integrated CDMO, providing end-to-end development solutions that span both drug substance and drug product. The integration of Avivia’s team enhances the group’s capacity to support complex formulation challenges from early-stage development through to GMP production.
“By integrating Avivia into the Ofichem Group, we are strengthening our ability to support customers from drug substance through R&D and small to large scale GMP manufacturing,” said Dr. Weite H. Oldenziel, CEO and owner of the Ofichem Group.
Avivia’s team of ten professionals brings over 25 years of expertise in formulation science. The acquisition builds on Ofichem’s existing capabilities in Ter Apel and Leiden and forms part of its wider investment and M&A strategy.
The company confirmed that it is actively exploring further expansion opportunities across Europe and North America, with a focus on innovation and early-phase contract manufacturing services.
